Lantheus Holdings, Inc (LNTH) — 分析摘要
Lantheus Holdings, Inc（LNTH）的市值为6.86十亿美元，最近一年的营收同比增长了+0.5%。净利润率为15.2%。当前市盈率为24.6倍。
核心要点
- 营收同比变化+0.5%
- 净利润率15.2%
- 市盈率24.6倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，LNTH的营收增长为+0.5%，市盈率为24.6倍。
Lantheus Holdings, Inc (LNTH)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
1,193
总部
NORTH BILLERICA, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。